Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available

Key Takeaways

• NEREUS (tradipitant) is now commercially available in the US as the first new prescription motion sickness drug approved in over 40 years
• Patients can order NEREUS directly through Vanda’s consumer platform at nereus.us, bypassing traditional pharmacy channels
• The drug represents a breakthrough for motion sickness prevention in adults, addressing an unmet medical need in this therapeutic area

---

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced on May 4, 2026, that NEREUS™ (tradipitant) is now commercially available across the United States for preventing motion-induced vomiting in adults. This milestone marks the first new prescription medicine approved for motion sickness in more than four decades.

Revolutionary Direct-to-Consumer Access

Vanda has launched an innovative direct-to-consumer ordering platform through nereus.us, allowing patients to access NEREUS without traditional pharmacy visits. This approach streamlines access to the breakthrough motion sickness treatment.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Addressing Decades-Old Treatment Gap

The commercial launch of NEREUS fills a significant void in motion sickness therapeutics. For over 40 years, patients have relied on older medications with limited efficacy or significant side effects. Tradipitant represents a new mechanism of action for preventing motion-induced nausea and vomiting.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Patient Benefits

The availability of NEREUS could transform treatment approaches for millions of Americans who experience motion sickness during travel, whether by car, plane, boat, or other transportation methods. The direct-to-consumer model may also influence how other pharmaceutical companies distribute specialized medications.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Clinical Significance

As the first new pharmacologic treatment for motion sickness in decades, NEREUS demonstrates Vanda Pharmaceuticals’ commitment to addressing underserved therapeutic areas. The drug’s approval by regulatory authorities validates tradipitant’s safety and efficacy profile for motion sickness prevention.

The launch positions Vanda to capture significant market share in the motion sickness treatment space, potentially generating substantial revenue from this previously stagnant therapeutic category.

---

Frequently Asked Questions

What does NEREUS approval mean for motion sickness patients?

Patients now have access to the first new prescription motion sickness treatment in over 40 years, offering a modern alternative to decades-old medications with potentially better efficacy and fewer side effects.

When will NEREUS be available to patients?

NEREUS (tradipitant) is available now across the United States through Vanda’s direct-to-consumer platform at nereus.us, allowing immediate access for eligible patients.

How does NEREUS compare to existing motion sickness treatments?

NEREUS represents the first new prescription option in over 40 years, suggesting it may offer advantages over older treatments, though specific comparative efficacy data would need to be reviewed from clinical trials.

Related coverage

• Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission
• MFN Drug Pricing Reshapes International Life Sciences Licensing Deals
• India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma